Abbvie Inc ABBV:NYSE

Last Price$139.17Cboe Real-Time Last Sale as of 11:42AM ET 8/08/22
Cboe Real-Time Quotes
Realtime quote and/or trade prices are not sourced from all markets
Today's Change+1.13(0.82%)
Bid (Size)$139.12 (113)
Ask (Size)$139.27 (105)
Day Low / High$138.04 - 140.17
Volume1.5 M
 

View Pharmaceuticals: Major IndustryPeer Comparison as of 08/08/2022

 

Abbvie Inc ( NYSE )

Price: $139.17
Change: +1.13 (0.82%)
Volume: 1.5 M
11:42AM ET 8/08/2022
 
 

Merck & Co Inc ( NYSE )

Price: $88.27
Change: +0.86 (0.98%)
Volume: 2.5 M
11:42AM ET 8/08/2022
 
 

Pfizer Inc ( NYSE )

Price: $49.57
Change: +0.30 (0.61%)
Volume: 4.7 M
11:42AM ET 8/08/2022
 
 

Eli Lilly and Co ( NYSE )

Price: $303.99
Change: +2.67 (0.89%)
Volume: 1.8 M
11:42AM ET 8/08/2022
 
 

N/A ( N/A )

Price: N/A
Change: N/A N/A
Volume: N/A
N/A
 

Read more news Recent News

AbbVie's Allergan Aesthetics Gets FDA Approval for Gel to Improve Jawline Definition
10:07AM ET 8/03/2022 MT Newswires

AbbVie's (ABBV) Allergan Aesthetics unit said Wednesday the US Food and Drug Administration approved its Juvederm Volux XC injectable gel to improve...

--Goldman Sachs Adjusts AbbVie's Price Target to $137 from $141, Keeps Neutral Rating
1:40PM ET 8/01/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

AbbVie's Neutral Rating Maintained at Goldman Even as Skyrizi Sales Jump
1:02PM ET 8/01/2022 MT Newswires

AbbVie's (ABBV) neutral rating at Goldman Sachs was maintained despite Q2 sales of plaque psoriasis drug Skyrizi significantly outperforming the firm's...

--UBS Adjusts AbbVie Price Target to $146 From $154, Maintains Neutral Rating
11:44AM ET 8/01/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Company Profile

Business DescriptionAbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL. View company web site for more details
Address1 North Waukegan Road
North Chicago, Illinois 60064-6400
Phone+1.847.932.7900
Number of Employees30,000
Recent SEC Filing08/04/202210-Q
Chairman & Chief Executive OfficerRichard A. Gonzalez
Vice Chairman & PresidentRobert A. Michael
Chief Financial Officer & Senior Vice PresidentScott T. Reents
Chief Scientific Officer, Senior VP-R&DThomas J. Hudson

Company Highlights

Price Open$138.04
Previous Close$138.04
52 Week Range$105.56 - 175.91
Market Capitalization$246.1 B
Shares Outstanding1.8 B
SectorHealth Technology
IndustryPharmaceuticals: Major
Current Dividend / Yield$1.41 / 4.09%
Dividend Ex-Date07/14/2022
Dividend Pay-Date08/15/2022
Dividend Yield 5 Year Average4.08%
Next Earnings Announcement11/04/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / Earnings19.80
Earnings per Share$6.90
Beta vs. S&P 500N/A
Revenue$32.8 B
Net Profit Margin22.18%
Return on Equity87.05%

Analyst Ratings as of 07/29/2022

Buy
12
Overweight
1
Hold
8
Underweight
1
Sell
1
Consensus RecommendationConsensus Icon
Powered by Factset